Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?

Differentiating post radiation necrosis from progression of glioma and pseudoprogression poses a diagnostic conundrum for many clinicians. As radiation therapy and temozolomide chemotherapy have become the mainstay of treatment for higher-grade gliomas, radiation necrosis and post treatment changes such as pseudoprogression have become a more relevant clinical problem for neurosurgeons and neurooncologists. Due to their radiological similarity to tumor progression, accurate recognition of these findings remains paramount given their vastly different treatment regimens and prognoses. However, no consensus has been reached on the optimal technique to discriminate between these two lesions. In order to clarify the types of imaging modalities for recurrent enhancing lesions, we conducted a systematic review of case reports, case series, and prospective studies to increase our current understanding of the imaging options for these common lesions and their efficacy. In particular, we were interested in distinguishing radiation necrosis from true tumor progression. A PubMed search was performed to include all relevant studies where the imaging was used to differentiate between radiation necrosis and recurrent gliomas with post-radiation enhancing lesions. After screening for certain parameters in our study, seventeen articles with 435 patients were included in our analysis including 10 retrospective and 7 prospective studies. The average time from the end of radiation therapy to the onset of a recurrent enhancing lesion was 13.2 months. The most sensitive and specific imaging modality was SPECT with a sensitivity of 87.6 % and specificity of 97.8 %. Based on our review, we conclude that certain imaging modalities may be preferred over other less sensitive/specific techniques. Overall, tests such as SPECT may be preferable in differentiating TP (tumor progression) from RN (radiation necrosis) due to its high specificity, while nonspecific imaging such as conventional MRI is not ideal.

[1]  R. Guillevin,et al.  [Imaging of gliomas]. , 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[2]  A. Porter,et al.  Hyperbaric oxygen therapy for radiation‐induced brain injury in children , 1997, Cancer.

[3]  Shigeaki Higashiyama,et al.  Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy , 2008, Journal of Nuclear Medicine.

[4]  Y. Yamada,et al.  Radiation necrosis following treatment of high grade glioma—a review of the literature and current understanding , 2012, Acta Neurochirurgica.

[5]  P. V. van Rijk,et al.  Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera--a pilot study. , 1999, Nuclear medicine communications.

[6]  S. Kosuda,et al.  Reassessment of quantitative thallium-201 brain SPECT for miscellaneous brain tumors , 1993, Annals of nuclear medicine.

[7]  W. Szeszkowski,et al.  Spectral changes in postoperative MRS in high-grade gliomas and their effect on patient prognosis. , 2009, Folia neuropathologica.

[8]  J. Pruim,et al.  What is the value of emission tomography studies in patients with a primary glioblastoma multiforme treated by 192Ir brachytherapy? , 2008, Acta Neurochirurgica.

[9]  B. Drayer,et al.  Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? , 1998, AJNR. American journal of neuroradiology.

[10]  R. Pacelli,et al.  Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: Tumour progression or radionecrosis? , 2009, Clinical Neurology and Neurosurgery.

[11]  T. Nose,et al.  The role of thallium-201 single photon emission tomography in the investigation and characterisation of brain tumours in man and their response to treatment , 2005, European Journal of Nuclear Medicine.

[12]  T. Mikkelsen,et al.  Permeability Estimates in Histopathology-Proved Treatment-Induced Necrosis Using Perfusion CT: Can These Add to Other Perfusion Parameters in Differentiating from Recurrent/Progressive Tumors? , 2011, American Journal of Neuroradiology.

[13]  A. McKinney,et al.  Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging , 2010 .

[14]  K Suzuki,et al.  Cerebral radiation necrosis with accumulation of thallium 201 on single-photon emission CT. , 1996, AJNR. American journal of neuroradiology.

[15]  P Van Tassel,et al.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.

[16]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[17]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Schmainda,et al.  Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.

[19]  Maria I. Argyropoulou,et al.  Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities , 2009, Journal of Neuro-Oncology.

[20]  Rakesh Kumar,et al.  Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced MRI in detection of recurrent glioma , 2011, Nuclear medicine communications.

[21]  Mark E Mullins,et al.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. , 2005, AJNR. American journal of neuroradiology.

[22]  Seung Hong Choi,et al.  Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade. , 2011, Radiology.

[23]  M. Senda,et al.  Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  A. Brandes,et al.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.

[25]  J. Marks,et al.  Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. , 1981, International journal of radiation oncology, biology, physics.

[26]  Dishan H. Gunawardana,et al.  Differentiation of tumor recurrence from radiation necrosis in high-grade gliomas using 201Tl-SPECT , 2008, Journal of Clinical Neuroscience.

[27]  A. Amin,et al.  Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results , 2012, Journal of Neuro-Oncology.

[28]  D. Kondziolka,et al.  Distinguishing Recurrent Tumor and Radiation Necrosis with Positron Emission Tomography versus Stereotactic Biopsy , 2000, Stereotactic and Functional Neurosurgery.

[29]  D. Kong,et al.  Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.

[30]  T. Nose,et al.  Correlation of histopathological factor of brain tumor and high thallium-201 uptake in single photon emission computed tomography. , 1996, Noshuyo byori = Brain tumor pathology.

[31]  Hong Liu,et al.  Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury , 2007, Journal of Neuro-Oncology.

[32]  T. Mikkelsen,et al.  Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion. , 2011, Neuro-oncology.

[33]  R. Gonzalez,et al.  Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. , 2010, Academic radiology.

[34]  Sotirios Bisdas,et al.  Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging. , 2011, Academic radiology.

[35]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[36]  J. Llamas-Elvira,et al.  Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  A. Alavi,et al.  New grading system of cerebral gliomas using positron emisson tomography with F-18 fluorodeoxyglucose , 1991, Journal of Neuro-Oncology.

[38]  T. Tominaga,et al.  Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography. , 2009, Neurologia medico-chirurgica.

[39]  Chen Wei-an,et al.  Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET , 2007, Journal of Neuro-Oncology.

[40]  R M Weisskoff,et al.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.

[41]  P. Burger,et al.  The morphologic effects of radiation administered therapeutically for intracranial gliomas.A Postmortem study of 25 cases , 1979, Cancer.

[42]  W. Olivero,et al.  The use of PET in evaluating patients with primary brain tumours: is it useful? , 1995, Journal of neurology, neurosurgery, and psychiatry.

[43]  K. Kang,et al.  Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI , 2010, Clinical Neurology and Neurosurgery.

[44]  A. Friedman,et al.  Treatment of radiation‐induced nervous system injury with heparin and warfarin , 1994, Neurology.

[45]  E. Melhem,et al.  Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas , 2010, Journal of magnetic resonance imaging : JMRI.

[46]  Stephen T. C. Wong,et al.  Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma , 2011, Journal of magnetic resonance imaging : JMRI.

[47]  A. Bozzao,et al.  Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis , 2011, Radiation oncology.

[48]  H. R. Arvinda,et al.  RETRACTED ARTICLE: Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging , 2009, Journal of Neuro-Oncology.

[49]  P. Kirchner,et al.  Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. , 1994, AJR. American journal of roentgenology.

[50]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[52]  Glyn Johnson,et al.  Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. , 2012, AJR. American journal of roentgenology.

[53]  G. Reynés,et al.  Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas , 2010, Journal of clinical neuroscience.

[54]  H. Yoo,et al.  Radiation-induced necrosis deteriorating neurological symptoms and mimicking progression of brain metastasis after stereotactic-guided radiotherapy. , 2007, Cancer research and treatment : official journal of Korean Cancer Association.

[55]  B. Bobek-Billewicz,et al.  Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. , 2010, Folia neuropathologica.